ADDISON, Ill., Nov. 12, 2013 /PRNewswire/ -- Ossur, a leading global provider of non-invasive orthopedic and prosthetic devices, and ArjoHuntleigh, a leading manufacturer of medical devices, have formalized a distribution agreement to deliver DVT prevention to patients after hospital discharge. ArjoHuntleigh's program will utilize Ossur's new DVTCareTM system. The agreement marks the launch of the companies' comprehensive DVTCare at Home program, which is intended to help reduce patients' risk of developing deep-vein thromboses (DVTs) by using Ossur's unique, portable compression device following their hospital discharge.
"We are pleased to be partnering with ArjoHuntleigh, a recognized market leader in acute care DVT prevention," said Olafur Glyfson, President of Ossur Americas. "This partnership enables us to provide our new DVT prevention system to more patients, and should ultimately lead to both improved clinical outcomes and reduced healthcare costs."
Each year, an estimated two million Americans are diagnosed with DVTs, a common but serious medical condition caused by the formation of blood clots in patients' lower limbs. 1 The most serious side effect of DVTs is pulmonary embolism, a deadly condition that often requires extensive patient care and re-hospitalization, and ultimately claims an estimated 300,000 U.S. lives annually. 2
"We are very excited about the launch of the DVTCare at Home Program, which extends ArjoHuntleigh's VTE prevention expertise into the post-acute care setting," said Brian Straeb, Vice President of Marketing for ArjoHuntleigh USA. ArjoHuntleigh's Flowtron® Active Compression Systems are among the most frequently utilized to reduce the risk of thrombus formation in hospitalized patients.
Clinical Bodies, Medicare Encourage DVT Prevention
Ossur's new DVTCare system has b
Copyright©2012 PR Newswire.
All rights reserved